参考文献/References:
[1] Roth GA,Mensah GA,Johnson CO,et al. Global burden of cardiovascular diseases and risk factors,1990-2019:update from the GBD 2019 study[J]. J Am Coll Cardiol,2020,76(25):2982-3021.
[2] Dadhania K,Ghosh B,Thota A,et al. Global,regional,and national trends in cardiovascular disease burden and risk factors in individuals under 20 from 1990 to 2019:insights from the GBD 2019 study[J]. J Am Coll Cardiol,2024,83(13):2321.
[3] 刘明波,王增武,樊静,等. 《中国心血管健康与疾病报告2023》要点解读[J]. 中国心血管病杂志,2024,22(7) :577-593.
[4] Mohammadnia N,Opstal TSJ,El Messaoudi S,et al. An update on inflammation in atherosclerosis:how to effectively treat residual risk[J]. Clin Ther,2023,45(11):1055-1059.
[5] Yang CH,Lv JJ,Li XY,et al. Global burden of asthma in young adults in 204 countries and territories,1990-2019:systematic analysis of the global burden of disease study 2019[J]. Prev Med Rep,2024,37:102531.
[6] Zhang B,Li ZF,An ZY,et al. Association between asthma and all-cause mortality and cardiovascular disease morbidity and mortality:a meta-analysis of cohort studies [J]. Front Cardiovasc Med,2022,9:861798.
[7] Hua ML,Li L,Diao LL. Bronchial asthma and risk of 4 specific cardiovascular diseases and cardiovascular mortality:a meta-analysis of cohort studies[J]. Eur Rev Med Pharmaco,2022,26(14):5081-5091.
[8] Picado C,Pernigotti A,Arismendi E. Asthma:a new cardiovascular risk factor? [J]Arch Bronconeumol,2019,55(7) :353-354.
[9] Wee JH,Park MW,Min C,et al. Association between asthma and cardiovascular disease[J]. Eur J Clin Invest,2021,51(3):e13396.
[10] Choi HG,Kwon MJ,Kim JH,et al. Association between asthma and cardiovascular diseases:a longitudinal follow-up study using a national health screening cohort[J]. World Allergy Organ J ,2024,17(6):100907.
[11] Naharro-González S,Lorente-Sorolla C,Rodrigo-Mu?oz JM,et al. Moderate-high blood eosinophilia is associated with increased hospitalization and other asthma comorbidities[J]. Biomolecules,2024,14(1):126.
[12] Chen H,Chen W,Zheng L. Genetic liability to asthma and risk of cardiovascular diseases:a Mendelian randomization study[J]. Front Genet,2022,13:879468.
[13] Valencia-Hernández CA,Del Greco MF,Sundaram V,et al. Asthma and incident coronary heart disease:an observational and Mendelian randomisation study[J]. Eur Respir J,2023,62(5):2301788.
[14] Aggarwal K,Bansal V,Mahmood R,et al. Asthma and cardiovascular diseases:uncovering common ground in risk factors and pathogenesis[J]. Cardiol Rev,2023 Aug 18. DOI:10.1097/CRD.0000000000000600. Online ahead of print.
[15] Scott HA,Ng SH,McLoughlin RF,et al. Effect of obesity on airway and systemic inflammation in adults with asthma:a systematic review and meta-analysis[J]. Thorax,2023,78 (10):957-965.
[16] Kim Y,Moonie S,Yoo JW,et al. Class Ⅲ obesity as a risk factor for persistent asthma[J]. Respir Care,2024 Aug 6:respcare.11934. DOI:10.4187/respcare.11934. Epub ahead of print.
[17] Karamzad N,Izadi N,Sanaie S,et al. Asthma and metabolic syndrome:a comprehensive systematic review and meta-analysis of observational studies[J]. J Cardiovasc Thorac,2020,12(2) :120-128.
[18] de Boer GM,Tramper-Stranders GA,Houweling L,et al. Adult but not childhood onset asthma is associated with the metabolic syndrome,independent from body mass index[J]. Resp Med,2021,188:106603.
[19] Christiansen SC,Schatz M,Yang SJ,et al. Hypertension and asthma:a comorbid relationship[J]. J Allergy Clin Immunol Pract,2016,4(1):76-81.
[20] Zolotareva O,Saik OV,K?nigs C,et al. Comorbidity of asthma and hypertension may be mediated by shared genetic dysregulation and drug side effects[J]. Sci Rep,2019,9(1):16302.
[21] Foer D,Beeler PE,Cui J,et al. Asthma exacerbations in patients with type 2 diabetes and asthma on glucagon-like peptide-1 receptor agonists[J]. Am J Resp Crit Care,2021,203(7):831-840.
[22]Wen L,Zhong W,Chai Y,et al. Association of metformin use with asthma exacerbation in patients with concurrent asthma and diabetes:a systematic review and meta-analysis of observational studies[J]. Can Respir J,2020:9705604.
[23] Tattersall MC. Asthma as a systemic disease:cardiovascular effects associated with asthma. Adv Exp Med Biol,2023,1426:77-100.
[24] de Caterina,R,Zampolli,A. From asthma to atherosclerosis--5-lipoxygenase,leukotrienes,and inflammation[J]. New Engl J Med,2004,350(1):4-7.
[25] Lewis MJ,Short AL,Lewis KE. Autonomic nervous system control of the cardiovascular and respiratory systems in asthma[J]. Resp Med,2006,100(10):1688-1705.
[26] Mayor S. Adult onset asthma may increase risk of heart disease and stroke[J]. BMJ,2016:i4685.
[27] Zhou Y,Liang ZS,Jin Y,et al. Shared genetic architecture and causal relationship between asthma and cardiovascular diseases:a large-scale cross-trait analysis[J]. Front Genet,2021,12:775591.
[28] Whatling C,McPheat W,Hersl?f M. The potential link between atherosclerosis and the 5-lipoxygenase pathway:investigational agents with new implications for the cardiovascular field[J]. Expert Opin Inv Drug,2007,16(12):1879-1893.
[29] Kyler KE,Jones BL. The chicken or the egg:the role of IL-6 in pediatric obese and allergen-exposed asthma[J]. J Allergy Clin Immun,2023,152(6):1420-1422.
[30] Tyrrell DJ,Goldstein DR. Ageing and atherosclerosis:vascular intrinsic and extrinsic factors and potential role of IL-6[J]. Nat Rev Cardiol,2021,18(1):58-68.
[31] Mehrabi Nasab E,Hassanzadeh Makoei R,Aghajani H,et al. IL-33/ST2 pathway as upper-hand of inflammation in allergic asthma contributes as predictive biomarker in heart failure[J]. ESC Heart Fail,2022,9(6):3785-3790.
[32] Casale TB,Foggs MB,Balkissoon RC. Optimizing asthma management:role of long-acting muscarinic antagonists[J]. J Allergy Clin Immun,2022,150(3):557-568.
[33] Rebordosa C,Plana E,Rubino A,et al. Risk assessment of acute myocardial infarction and stroke associated with long-acting muscarinic antagonists,alone or in combination,versus long-acting β2-agonists[J]. Int J Chron Obstruct Pulmon Dis,2022,17:1715-1733.
[34] Qin J,Wang G,Han D. Long-term safety of tezepelumab in patients with asthma:a systematic review and meta-analysis of randomized controlled trials[J]. J Asthma,2024,2:1-10.
[35] Xu R,Fu J,Hu Y,et al. Roflumilast-mediated phosphodiesterase 4D inhibition reverses diabetes-associated cardiac dysfunction and remodeling :effects beyond glucose lowering[J]. Diabetes,2022,71(8):1660-1678.
[36]Xu B,Xu J,Cai N,et al. Roflumilast prevents ischemic stroke-induced neuronal damage by restricting GSK3β-mediated oxidative stress and IRE1α/TRAF2/JNK pathway[J]. Free Radical Bio Med,2021,163:281-296.
[37]White WB,Cooke GE,Kowey PR,et al. Cardiovascular safety in patients receiving roflumilast for the treatment of COPD[J]. Chest,2013,144(3):758-765.
[38] Villani AP,Pavel AB,Wu J,et al. Vascular inflammation in moderate-to-severe atopic dermatitis is associated with enhanced Th2 response[J]. Allergy,2021,76(10):3107-3121.
[39] Gibson PG,Prazma CM,Chupp GL,et al. Mepolizumab improves clinical outcomes in patients with severe asthma and comorbid conditions[J]. Respir Res,2021,22(1):171.
[40] Lee PH,Hong J,Jang AS. N-acetylcysteine decreases airway inflammation and responsiveness in asthma by modulating claudin 18 expression[J]. Korean J Intern Med,2020,35(5):1229-1237.
[41] Pasupathy S,Tavella R,Grover S,et al. Early use of N-acetylcysteine with nitrate therapy in patients undergoing primary percutaneous coronary intervention for ST-segment-elevation myocardial infarction reduces myocardial infarct size (the NACIAM trial [N-acetylcysteine in acute myocardial infarction])[J]. Circulation,2017,136(10):894-903.
相似文献/References:
[1]白春兰,张军.正五聚蛋白-3:新型心血管病炎性标志物[J].心血管病学进展,2016,(1):87.[doi:10.16806/j.cnki.issn.1004-3934.2016.01.023]
BAI Chunlan,ZHANG Jun.Pentraxin-3: A Novel Inflammation Biomarker for Cardiovascular Disease[J].Advances in Cardiovascular Diseases,2016,(3):87.[doi:10.16806/j.cnki.issn.1004-3934.2016.01.023]
[2]任茂佳,贺文帅,张琪,等.围绝经期对心血管疾病相关危险因素的影响[J].心血管病学进展,2019,(6):911.[doi:10.16806/j.cnki.issn.1004-3934.2019.06.018]
REN Maojia,HE Wenshuai,ZHANG Qi,et al.Effects of Perimenopause on Cardiovascular Risk Factors[J].Advances in Cardiovascular Diseases,2019,(3):911.[doi:10.16806/j.cnki.issn.1004-3934.2019.06.018]
[3]尹琳 黄从新.JP2蛋白和心血管疾病的研究进展[J].心血管病学进展,2019,(7):1004.[doi:10.16806/j.cnki.issn.1004-3934.2019.07.010]
YIN Lin HUANG Congxin.Research Progress of JP2 Protein and Cardiovascular Disease[J].Advances in Cardiovascular Diseases,2019,(3):1004.[doi:10.16806/j.cnki.issn.1004-3934.2019.07.010]
[4]朱峰 汪汉 蔡琳.抗体与心血管疾病[J].心血管病学进展,2019,(7):1007.[doi:10.16806/j.cnki.issn.1004-3934.2019.07.011]
ZHU FengWANG HanCAI Lin.Antibodies and Cardiovascular Disease[J].Advances in Cardiovascular Diseases,2019,(3):1007.[doi:10.16806/j.cnki.issn.1004-3934.2019.07.011]
[5]邱明仙 王正龙 许官学.心肌肌球蛋白结合蛋白-C磷酸化与心血管疾病关系的研究进展[J].心血管病学进展,2019,(7):1015.[doi:10.16806/j.cnki.issn.1004-3934.2019.07.013]
QIU MingxianWANG ZhenglongXU Guanxue.Research Progress of the Relationship Between Cardiac Myosin Binding Protein-C and Cardiovascular Disease[J].Advances in Cardiovascular Diseases,2019,(3):1015.[doi:10.16806/j.cnki.issn.1004-3934.2019.07.013]
[6]姬楠楠 杨晓静 谢勇.单核细胞/高密度脂蛋白比值与心血管疾病的研究进展[J].心血管病学进展,2019,(7):1019.[doi:10.16806/j.cnki.issn.1004-3934.2019.07.014]
JI Nannan YANG Xiaojing XIE Yong.Monocyte/High-density Lipoprotein Ratio and Cardiovascular Disease[J].Advances in Cardiovascular Diseases,2019,(3):1019.[doi:10.16806/j.cnki.issn.1004-3934.2019.07.014]
[7]渠海贤 李涛 程流泉.人工智能在心脏磁共振成像中的应用进展[J].心血管病学进展,2019,(5):659.[doi:10.16806/j.cnki.issn.1004-3934.2019.05.001]
[8]侯冬华 郝丽荣.长正五聚蛋白3在动脉粥样硬化和心血管疾病中作用研究的新进展[J].心血管病学进展,2019,(5):805.[doi:10.16806/j.cnki.issn.1004-3934.2019.05.035]
HOU Donghua H AO Lirong.The Study of Atherosclerosis and Cardiovascular Diseases with Pentapycin 3[J].Advances in Cardiovascular Diseases,2019,(3):805.[doi:10.16806/j.cnki.issn.1004-3934.2019.05.035]
[9]张维 张恒 康品方.外泌体在心血管疾病中的研究进展[J].心血管病学进展,2019,(5):818.[doi:10.16806/j.cnki.issn.1004-3934.2019.05.038]
Zhang WeiKang Pinfang.Exosome in Cardiovascular Diseases[J].Advances in Cardiovascular Diseases,2019,(3):818.[doi:10.16806/j.cnki.issn.1004-3934.2019.05.038]
[10]韦莹 刘书旺 李蕾 崔鸣.生长分化因子-15在心房颤动中的研究进展[J].心血管病学进展,2019,(8):1073.[doi:10.16806/j.cnki.issn.1004-3934.2019.08.001]
WEI Ying,LIU Shuwang,LI Lei,et al.Growth Differentiation Factor-15 in Development of Atrial Fibrillation[J].Advances in Cardiovascular Diseases,2019,(3):1073.[doi:10.16806/j.cnki.issn.1004-3934.2019.08.001]